通过改善肠道屏障功能和调节肠道微生物群,Protopine可以缓解德克斯硫酸诱导的性结肠炎
Meishan Yue1, Jialu Huang1, Xiaolan Ma1
1College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.
Molecules (Basel, Switzerland)
|July 14, 2023
概括
普罗托平 (PRO) 通过减少炎症,修复肠道屏障和重新平衡肠道微生物群,有效治疗小鼠的性结肠炎 (UC). 这种天然化合物为炎症性肠病 (IBD) 提供了有前途的治疗方法.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC),是一种炎症性肠病 (IBD),涉及肠道屏障损伤和肠道微生物群失衡.
- 普罗托 (PRO) 是一种来自马克莱亚cordata的异类化物,具有已知的抗炎性质.
研究的目的:
- 为了研究Protopine (PRO) 对肠粘膜屏障和肠道微生物群的治疗作用,在硫酸 (DSS) 诱导的大肠炎的小鼠模型中.
主要方法:
- 在C57BL/6J小鼠中使用3%的饮用水中的DSS诱导了急性结肠炎.
- 小鼠每天口服Protopine (PRO),持续7天.
- 分析了对大肠炎症状,炎症标志物,肠道屏障完整性和肠道微生物群组成的影响.
主要成果:
- 普罗托平 (PRO) 显著缓解了DSS诱导的大肠炎症状,并抑制了与炎症相关的基因表达.
- PRO恢复了结肠粘素分泌,促进了紧结蛋白的表达,增强了肠道屏障的完整性.
- PRO纠正了肠道微生物群的失调,减少了有害细菌 (蛋白质细菌,埃舍里希亚-希格拉,菌) 和增加了有益的细菌 (Firmicutes,Akkermansia).
结论:
- 普罗托平 (PRO) 在性结肠炎中显示出显著的治疗潜力.
- 通过抑制炎症,维持肠道屏障功能和调节肠道微生物群组成来起作用.
更多相关视频
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
505
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
505
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
247
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
247
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
468
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
468
Inflammatory Bowel Disease IV: Pharmacological Management
154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
154


